In February 2019 the South African Health Products Regulatory Authority (SAHPRA) received reports suggesting fraudulent activity implicating a small sector of the authority and an external stakeholder. SAHPRA’s acting-CEO, the Board and the Health Minister reported the allegations to the Special Investigating Unit (SIU) and...
The South African Health Products Regulatory Authority (SAHPRA) notes with concern the statement made on Cape Talk Radio that the regulatory authority has issued the first commercial licences for the growing and manufacturing of cannabis. The mandate of the regulatory authority is to issue licences...
The South African Health Products Regulatory Authority (SAHPRA) has learned about the safety concerns regarding the presence of a nitrosamine impurity called NDMA in ranitidine-containing medicines. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on the results of...
SAHPRA is pleased to announce the appointment of a new Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, who will commence with this role in January 2020. Dr Semete-Makokotlela holds a Ph.D. in Biochemistry (North-West University) and an MSc in Management Finance and Investment from Wits Business...
Mr Khamusi Mutoti, Biological Medicine Manager at SAHPRA, was elected the Chairperson of the African Blood Regulator’s Forum (ABRF) during the African Medicines Regulation Conference (AMRC) held at Elephant Hill Hotel, Victoria Falls, Zimbabwe on 2 – 4 October 2019. Mr Mutoti who is also an...